Egyptian Academic Journal of Biological Sciences is the official English language journal of the Egyptian Society for Biological Sciences, Department of Entomology, Faculty of Sciences Ain Shams University.

C. Physiology & Molecular Biology journal is one of the series issued twice by the Egyptian Academic Journal of Biological Sciences, and is devoted to publication of original papers that elucidate important biological, chemical, or physical mechanisms of broad physiological significance.

http://eajbsc.journals.ekb.eg/

Citation: Egypt. Acad. J. Biolog. Sci. (C. Physiology and Molecular biology) Vol. 11(2) pp. 71-83(2019)
Prevalence and Severity of Anemia in CKD patients

Raed Alharbi
Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Albaha University, Albaha, Kingdom of Saudi Arabia.
E.Mail: ralharbi@bu.edu.sa

INTRODUCTION
Anemia is a well-recognized initial complication and has a correlation with the progression of chronic kidney diseases (CKD), the prospective necessity for blood transfusion, substandard quality of life as well as with the huge hike in morbidity and mortality Smith Jr (2010), van Nooten et al. (2010), Farag et al. (2011), Iseki and Kohagura (2007), (Tamura et al., 2016, Moranne et al., 2009, Herzog et al., 2004). The Prevalence of anemia with the aggrandized risk of cardiovascular (Strippoli et al., 2004, Wheeler et al., 2003, Thorp et al., 2009, Servilla et al., 2009, Pereira, 2002, Silverberg et al., 1998) and cerebrovascular(Abramson et al., 2003) phenomena leads to the progression of CKD, and hospitalization (Keane et al., 2003, Levin et al., 2005, Staples et al., 2009). Anemia in CKD patients is a clinically considerable burden, and it turns out to be predominant with the reduction of glomerular filtration rate (GFR)
Progressive enhancement in anemia with the decline of the estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m² was exhibited in a population-based investigation using the National Health and Nutrition Examination Survey (NHANES) in the USA (Astor et al., 2002). Its type in CKD patients is normocytic, normochromic and hypo-proliferative; it can be caused by erythropoietin (EPO) deficiency from declined renal mass, different types of pro-inflammatory mediators, nutritional and iron deficiencies which probably affect the process of erythropoiesis in patients suffering from CKD (Babitt and Lin, 2012). Of note, anemia is an ultimate result of CKD as the kidneys synthesize and secrete the majority of EPO (Mercadal et al., 2012, Jacobson et al., 1957).

CKD is categorized into five stages (CKD-1, CKD-2, CKD-3, CKD-4, and CKD-5) based on the amount of kidney function remaining (glomerular filtration). The classification system refers to stage-1 as the least severe while the stage-5 as the most severe stage of the kidney damage (Tomasello, 2008). There have been several recent reports of population-based investigation about the prevalence of anemia in CKD patients. Prevalence of anemia was found to be 15.4% in patients with CKD stage 1–5 as compared to 7.5% in non-CKD population as per the recent NHANES report which indicates the association of anemia with different CKD stages (Stauffer and Fan, 2014). The association of anemia with CKD stages was reported in a Chinese study (Li et al., 2016). However, there are limited data as regards the prevalence of anemia in CKD patients in Jazan region, the Kingdom of Saudi Arabia (KSA). Hence, this study was intended to investigate the prevalence of anemia among the patients of CKD across the gender line and the different stage of CKD in Jazan region, KSA.

MATERIALS AND METHODS

Study Design and Participants:

This study is a cross-sectional analysis that included all CKD patients (n=228) applied to King Fahad Central Hospital, Jazan, KSA for receiving treatment for 24 months from January 2016 to December 2017.

Ethical Considerations:

The ethics committee of granting approved this study was King Fahad central hospital research ethics committee (Registry no. 083)

Exclusion criteria

Patients less than 18 years old, mentally patients, and severe cardiac and pulmonary disease, smokers, pregnant women, patients with kidney transplant, malignancy, patients with chronic infections were excluded.

Data Collection:

Demographic (age and gender) and laboratory data: serum haemoglobin (Hb) (g/dL), creatinine (umol/L), iron (umol/L), total iron binding capacity (TIBC) in umol/L, ferritin (mg/L), RDW%, Hematocrit (HCT%), mean corpuscular volume (MCV) in femtolitre (fL), mean corpuscular haemoglobin concentration (MCHC) in g/dL and mean corpuscular haemoglobin (MCH) in picogram (pG) were collected. Transferrin saturation (TSAT %) was calculated using serum iron and TIBC data of each patient. Calculation of the eGFR was accomplished by using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation that is preferable to serve the purpose of the investigation (Levey et al., 2009).

\[
\text{CKD-EPI estimated GFR (eGFR) = 141 × min (SCr mg/dL)/κ, 1)α × max (SCr/κ, 1)^{−1.209 × 0.993^{age} × 1.018 (if female)} × 1.159 (if Black), where eGFR is estimated glomerular filtration rate in mL/min/1.73 m^2, SCr is standardized serum creatinine, κ is 0.7 for females and 0.9 for males, α is −0.329 for}
\]

(McClellan et al., 2004).
females and −0.411 for males, age in years, min indicates the minimum of SCr/κ or 1, and max indicates the maximum of SCr/κ or 1 (Levey and Stevens, 2010, Matsushita et al., 2010).

**Definitions:**
With the aim of performing cross-sectional analysis (prevalence) of anemia in CKD patients (n=228) they were stratified according to their eGFRs into five different stages as per kidney disease outcome quality initiative (KDOQI) (Kopple, 2001) as follows: eGFR above 90 mL/min/1.73 m² (CKD stage-1), eGFR 60–90 mL/min/1.73 m² (CKD stage-2), eGFR 30–59 mL/min/1.73 m² (CKD stage-3), eGFR 15–29 mL/min/1.73 m² (CKD stage-4) and eGFR: <15 mL/min/1.73 m² (CKD stage-5). Stage-1, stage-2, and stage-3 in this study have been defined as the early stages of CKD while stage-4 and stage-5 as advanced stages of CKD. Patients with Hb <10 g/dL were defined as severely anemic. The patients were evaluated based on four different sub-groups (Hb <10 g/dL, Hb=10-11 g/dL, Hb=11-12 g/dL, and Hb >12 g/dL). The reason behind the first two sub-groupings: Hb <10 g/dL and Hb=10-11 g/dL is the fact that the ESA in CKD patients starts when the Hb level drops below 10 g/dL with the setting of a therapeutic target, not over and above 11.5 g/dL as per recommendation of KDIGO (The Kidney Disease: Improving Global Outcomes) guidelines (McMurray et al., 2012). We defined anemia as a Hb concentration is less than 13 g/dL in males and less than 12 g/dL in females according to the KDIGO guidelines or a state receiving ESA (Colantonio et al., 2016).

**Statistical Analysis:**
The data collected were reviewed, inquisitively verified and statistically analyzed to get the descriptive statistic (mean, STD., median 95% CI, IQR). All analyses were executed in the International Business Machines Corporation (IBM) Statistical Package for Social Sciences (SPSS) statistics version 21 (IBM Corp., Armonk, NY, USA). Statistical significance was considered when P<0.05.

**RESULTS**
**Characteristics of the patients**
In total CKD patients (n=229), including female (n=106, 46.28%) and male (n=123, 53.71%) who satisfied the criteria for investigation were recruited over a time period of 24 months from January 2016 to December 2017. The mean age of all the participants was 51.17 ± 15.37 years, and that of male patients and female patients was 54.94 ± 17.98 and 55.13 ± 14.27 years, respectively. The overall characteristics of CKD patients, as well as the patients’ characteristics by gender and CKD stage sub-groups, are summarized well-summarized in table 1.
Table 1. Baseline characteristics of CKD patients (n=229) and patients’ characteristics according to gender and CKD stage sub-groups.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Statistics</th>
<th>Overall</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Median (IQR)</td>
<td>Mean ± SD</td>
<td>Median (IQR)</td>
</tr>
<tr>
<td>Age</td>
<td>Median (IQR)</td>
<td>52 (40-82)</td>
<td>56 (40-68)</td>
<td>54.5 (47-65)</td>
</tr>
<tr>
<td></td>
<td>Mean ± SD</td>
<td>51.17 ± 15.37</td>
<td>54.94 ± 17.98</td>
<td>55.13 ± 14.27</td>
</tr>
<tr>
<td>eGFR (mL/min/1.73 m²) CKD-EPI</td>
<td>Mean ± SD</td>
<td>6.5 (4.6-22)</td>
<td>7 (5.1-25)</td>
<td>5.65 (4.5-12.53)</td>
</tr>
<tr>
<td>CKD stage-1</td>
<td>N (%)</td>
<td>2.65</td>
<td>3.25</td>
<td>1.89</td>
</tr>
<tr>
<td>CKD stage-2</td>
<td>N (%)</td>
<td>4.82</td>
<td>4.88</td>
<td>4.72</td>
</tr>
<tr>
<td>CKD stage-3</td>
<td>N (%)</td>
<td>15.16</td>
<td>13.82</td>
<td>12.26</td>
</tr>
<tr>
<td>CKD stage-4</td>
<td>N (%)</td>
<td>8.77</td>
<td>65.85</td>
<td>4.72</td>
</tr>
<tr>
<td>CKD stage-5</td>
<td>N (%)</td>
<td>70.81</td>
<td>12.2</td>
<td>76.42</td>
</tr>
<tr>
<td>Hb (g/dL)</td>
<td>Median (IQR)</td>
<td>11.8 (10.15-13.75)</td>
<td>10.25 (9.01-11.7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mean ± SD</td>
<td>11.31 ± 0.238</td>
<td>12.02 ± 1.79</td>
<td>10.49 ± 2.02</td>
</tr>
<tr>
<td>&lt;10 (g/dL)</td>
<td>N (%)</td>
<td>16.16</td>
<td>16.26</td>
<td>16.04</td>
</tr>
<tr>
<td>&gt;11 (g/dL)</td>
<td>N (%)</td>
<td>33.62</td>
<td>16.26</td>
<td>20.75</td>
</tr>
<tr>
<td>Crea umol/L</td>
<td>Median (IQR)</td>
<td>693 (208.76-920)</td>
<td>676.5 (334.800.25)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mean ± SD</td>
<td>610.97 ± 365.47</td>
<td>655.33 ± 405.25</td>
<td>582.71 ± 312.59</td>
</tr>
<tr>
<td>Iron umol/L</td>
<td>Median (IQR)</td>
<td>11 (7.9-14.76)</td>
<td>11 (7.95-15.04)</td>
<td>9.34 (7.3-13.02)</td>
</tr>
<tr>
<td></td>
<td>Mean ± SD</td>
<td>11.39 ± 5.58</td>
<td>12.09 ± 5.66</td>
<td>10.65 ± 5.44</td>
</tr>
<tr>
<td>TIBC umol/L</td>
<td>Median (IQR)</td>
<td>36 (33.42)</td>
<td>34.4 (32.75-38.25)</td>
<td>38 (34.75-44)</td>
</tr>
<tr>
<td></td>
<td>Mean ± SD</td>
<td>31.35 ± 20.54</td>
<td>36.21 ± 9.11</td>
<td>42.39 ± 27.38</td>
</tr>
<tr>
<td>TSAT (%)</td>
<td>Median (IQR)</td>
<td>27.9 (21.15-38.62)</td>
<td>28.89 (23.88-41.93)</td>
<td>25.46 (18.56-34.39)</td>
</tr>
<tr>
<td></td>
<td>Mean ± SD</td>
<td>31.35 ± 16.34</td>
<td>34.94 ± 17.98</td>
<td>28.20 ± 15.01</td>
</tr>
<tr>
<td>Ferritin (umol/L)</td>
<td>Median (IQR)</td>
<td>818.5 (335.38-965.75)</td>
<td>830 (315.33-1040)</td>
<td>366 (334.6-871)</td>
</tr>
<tr>
<td></td>
<td>Mean ± SD</td>
<td>728.34 ± 526.33</td>
<td>751.91 ± 459.45</td>
<td>704.76 ± 557.53</td>
</tr>
<tr>
<td>RDW%</td>
<td>MEDIAN (IQR)</td>
<td>16.4 (14.9-18)</td>
<td>15.1 (14-16.5)</td>
<td>16.5 (14.5-18)</td>
</tr>
<tr>
<td>HCT %</td>
<td>MEDIAN (IQR)</td>
<td>33.3 (29.3-36.7)</td>
<td>37.3 (31.7-43.3)</td>
<td>33.3 (28.9-36.8)</td>
</tr>
<tr>
<td>MCV (FL)</td>
<td>MEDIAN (IQR)</td>
<td>84.9 (78.6-90.4)</td>
<td>84.2 (78.9-88.85)</td>
<td>85.9 (80.4-92.17)</td>
</tr>
<tr>
<td>MCH (PG)</td>
<td>MEDIAN (IQR)</td>
<td>26.7 (24.65-29)</td>
<td>26.9 (25.03-28.8)</td>
<td>27.1 (24.8-29.1)</td>
</tr>
<tr>
<td>MCHC (g/dL)</td>
<td>MEDIAN (IQR)</td>
<td>31.6 (30.8-32.4)</td>
<td>31.9 (31.05-32.9)</td>
<td>31.5 (30.8-32.3)</td>
</tr>
</tbody>
</table>

CKD= chronic kidney disease, eGFR=estimated glomerular filtration rate, TSAT=transferrin saturation, TIBC=total iron binding capacity, RDW= Red blood cell distribution width, HCT% = Hematocrit, MCV= mean corpuscular volume, MCHC= mean corpuscular haemoglobin concentration, MCH =mean corpuscular haemoglobin, fl = femtolitre and pG = pictogram.

The Prevalence of Anemia in Overall CKD Patients:

In totality among 229 CKD patients ranging from stage-1 to stage-5, 157 (69%) and 72 (31%) patients were anemic and non-anemic, respectively (Fig. 1). The mean age of anemic and non-anemic CKD patients were 52.73 ± 15.82 and 60.04 ± 16.42, respectively (P<0.0019). The mean eGFR of anemic and non-anemic CKD patients was 10.14 ±13.57 and 35.74 ±30.36 (P<0.001). Comparison of anthropometric data and the laboratory parameters of anemic and non-anemic CKD patients with the level of their significance (P<0.001) were summarized in (Table 2). Female CKD patients (36%) were found to be more anemic than male patients (32%) (Fig. 2).
Anemia prevalence and severity in CKD

Fig. 1 Percentage distribution of anemic and non-anemic CKD patients recruited for the study

Fig. 2 Percentage distribution of anemic and non-anemic CKD patients by gender recruited for the study

Table 2. Comparisons of Anthropometric data and laboratory parameters between anemic and non-anemic CKD patients

<table>
<thead>
<tr>
<th>Variables</th>
<th>Anemic (n=157)</th>
<th>Non-anemic (n=72)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anthropometric data</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, yr</td>
<td>52.73 ± 15.82</td>
<td>60.04 ± 16.42</td>
<td>0.0019</td>
</tr>
<tr>
<td><strong>Laboratory parameters</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hb (g/dL)</td>
<td>9.9 ± 1.491</td>
<td>14.38 ± 1.58</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Crea umol/L</td>
<td>711.62 ± 311.90</td>
<td>391.52 ± 379.30</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>eGFR (mL/min/1.73 m²) CKD=EPI</td>
<td>10.14 ± 13.57</td>
<td>35.74 ± 30.36</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Iron umol/L</td>
<td>10.82 ± 5.73</td>
<td>13.5 ± 4.45</td>
<td>0.002</td>
</tr>
<tr>
<td>TIBC umol/L</td>
<td>38.13 ± 22.4</td>
<td>43.23 ± 10.45</td>
<td>0.041</td>
</tr>
<tr>
<td>TSAT (%)</td>
<td>31.06 ± 17.6</td>
<td>32.4 ± 11.93</td>
<td>0.5</td>
</tr>
<tr>
<td>Ferritin umol/L</td>
<td>738.39 ± 538.85</td>
<td>674.22 ± 458.6</td>
<td>0.5</td>
</tr>
<tr>
<td>RDW%</td>
<td>16.64 ± 2.61</td>
<td>14.79 ± 2.19</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HCT %</td>
<td>31.5 ± 4.75</td>
<td>44.71 ± 4.65</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>MCV FL</td>
<td>83.89 ± 9.18</td>
<td>85.5 ± 5.97</td>
<td>0.11</td>
</tr>
<tr>
<td>MCH pG</td>
<td>26.46 ± 3.20</td>
<td>27.57 ± 2.23</td>
<td>0.003</td>
</tr>
<tr>
<td>MCHC g/dL</td>
<td>31.29 ± 2.69</td>
<td>34 ± 15.81</td>
<td>0.25</td>
</tr>
</tbody>
</table>

eGFR=estimated glomerular filtration rate, TSAT=transferrin saturation, TIBC=total iron binding capacity, RDW= Red blood cell distribution width, HCT%= Hematocrit, MCV= mean corpuscular volume, MCHC=mean corpuscular haemoglobin concentration, MCH=mean corpuscular haemoglobin, FL= femtolitre and pG = pictogram.
Anemic Characteristics of CKD Patients by Gender and eGFR:

All the study patients were stratified based on their GFR into five CKD stages (from stage-1 to stage-5). 70.61% of total patients belonged to stage-5 category while stage-3: 13.16%, stage-4: 8.77%, stage-2: 4.82% and stage-1: 2.63%. Stage-4 (N%-65.81) was the most common CKD condition in the male category while stage-5 (N%-76.42%) in female patients (Table 1). The distribution of the differences in the prevalence level of Hb between male and female CKD patients are shown in (Fig. 3). The patients were stratified according to their Hb level into four different categories: Hb <10 g/dL, Hb = 10-11 g/dL, Hb =11-12 g/dL and Hb >12 g/dL. A total of 41.51% female patients and 21.14% of male CKD patients had Hb level <10 g/dL (male to female ratio of Hb <10g/dL = 1:2). The Hb level prevalence < 12 g/dL (the level of Hb at which the anemia workup ought to be begun) for male and female patients was 55.29% and 79.25%, respectively, while that < 11 g/dL (the level of Hb at which the EPO therapy for treating anemia ought to be started) for male and female was found to be 39.03% and 63.21%, respectively.

![Fig. 3 Distribution of level of the prevalence of Hb in the study patients according to gender](image)

The prevalence of anemia across all the five stages of CKD (stage-1 to stage-5) was assessed. The level of Hb<12 g/dL was reported to be 13.37%, 18.18%, 23.33%, 45% accordingly while that was evaluated the level of Hb<11 g/dL, was found to be 15.7%, 16.09%, 19.66%, 40%, and 43.36%, respectively (Fig. 4). Severe anemia (Hb<10 g/dL category) was observed in the advanced stages of CKD (stage-4 and stage-5) with the decline of renal functions (Fig. 4). The overall prevalence of anemia correlated with the advancement in CKD stages (stage-4 and stage-5) which means that anemia becomes more prevalent as the progression of the diseases and decline of kidney function. Also, CKD patients across the stages ranging from stage-1 to stage-4 while anemia prevalence was almost equally distributed between male and female in stage-5 (Fig. 5). The severity of anemia was more predominant in female patients than their male counterparts in the stage-4 to stage-5 (Fig. 6). The overall status of anemia and comparison prevalence of anemia under the four different categories of Hb between male and female across all the CKD stages are summarized in (Fig. 5 and Fig. 6).
Anemia prevalence and severity in CKD

Fig. 4. The distribution of patients according to their haemoglobin levels in the different stages of the estimated glomerular filtration rate (GFR).

Fig. 5. The prevalence of anemia among male and female CKD patients by CKD stages. CKD = chronic kidney disease, M = males, F = females.

Fig. 6. Overall status and comparison of prevalence of anemia among male and female CKD patients by CKD stages. CKD = chronic kidney disease, M = males, F = females.
DISCUSSION

The foreground of this study is the heightened prevalence of anemia in CKD patients recruited from Jazan region, KSA, at King Fahad Central Hospital for the period of 24 months from January 2016 to December 2017. Remarkably, this study reveals that the overall prevalence of anemia in CKD patients (mean age: 51.17±15.37) based on the definition of anemia as a Hb concentration is less than 13 g/dL in males and less than 12 g/dL in females according to the KDIGO guidelines or a state receiving ESA was 69%. The anemia prevalence in China including CKD patients of all the stages from 1–5 with age range 18–75 reported that 51.5% of patients were anemic (Li et al., 2016), 32.3% of the patients were diagnosed to be anemic in a Japanese study including CKD patients (n=2930) of advanced CKD stages from 3–5 (Akizawa et al., 2011). A prevalence of anemia was found to be 46% and 15.4% in the Chronic Renal Insufficiency Cohort (CRIC) study in the USA, which investigate 762 CKD patients (stage 1–5) with the age of more than 55 year and in NHANES study comprising 410 CKD (stage 1–5) patients older than 18 years, respectively (Stauffer and Fan, 2014, Tamura et al., 2016). The potential explanation of the higher prevalence of anemia in our study might be owing to the difference in the study population and the geographical variation, therefore, a larger population-based study is required to confirm it (Obrador et al., 2001).

Additionally, the trends of anemia differ gender wise where the female CKD patients (N%=36) was found to be more anemic than male CKD patients (N% =32%) which indicates that the female gender could be considered as one of the various risk factors associated with the worsening of anemia in CKD patients. This finding is similar to the findings of a study that was done in the USA (Hsu et al., 2002). The results of our study show that the prevalence pattern of anemia across the different gender of CKD patients is significantly different for the male and female for the level of Hb at which the anemia assessment is necessitated and Hb level at which anemic patients need EPO therapy. The prevalence was also noticed to be enhanced with the progression of CKD. Anemic patients have twofold their relative risk of death when CKD is present, and threefold their risk if they have the cardio-renal anemia syndrome (Silverberg et al., 2003).

In our study the four different categories of CKD patients stratified based on their Hb level, including Hb <10 g/dL, Hb = 10-11 g/dL, Hb =11-12 g/dL and Hb >12 g/d across all the stages of CKD. This stratification demonstrated that a total of 41.51% female patients and 21.14% of male CKD patients had Hb level <10 g/dL (male to female ratio of Hb <10g/dL = 1:2). Additionally, Hb level prevalence < 12 g/dL for male and female patients was 55.29% and 79.25%, respectively, while that < 11 g/dL for male and female was found to be 39.03% and 63.21% that is similar to the results demonstrated in a large a multi-center cross-sectional study that included the patients with different chronic CKD (n = 250) from 11 different medical centers of nephrology well-distributed all over the KSA (Hsu et al., 2002, Shaheen et al., 2011). In our study patients stratified based on their GFR into five CKD stages, 70.61% (maximum) of the total patients belonged to stage-5 category while stage-3: 13.16 %, stage-4: 8.77%, stage-2: 4.82% and stage-1: 2.63 % (minimum). Stage-4 (N%=65.81) was the most common CKD condition in male category while stage-5 (N% = 76.42%) in female patients.

Our work highlights the severity and prevalence of anemia was observed to be comparatively higher in the advanced stages of CKD (stage-4
Anemia prevalence and severity in CKD

Anemia prevalence and severity in CKD patients enhances from 26% to 75% when the renal function declines from > 60 ml/min (stage-2) to < 15 ml/min (stage-5) most likely owing to the deficiency of EPO (McClellan et al., 2004). The prevalence pattern of anemia was shown to be increased with the progression of the CKD stages 1 to 5 at Hb<12 g/dL as well as Hb<11 g/dL in a study in Boston, the USA (Kazmi et al., 2001). The prevalence pattern of anemia in our study across all the five stages of CKD (stage-1 to stage-5) for the level of Hb<12 g/dL was reported to be 13.37%, 18.18%, 23.33%, 45% and 81.22% accordingly while that for the level of Hb<11 g/dL was found to be 15.7%, 16.09%, 19.66%, 40% and 43.36%, respectively, which is similar to the finding of a study in KSA (Shaheen et al., 2011) and slightly lower than the findings of the study in Boston, the USA which is most probably due to difference in population (Kazmi et al., 2001). In addition to that if the therapeutic burden of CKD patients with the Hb<11 g/dL is estimated in the USA as per a study carried out by (Kazmi et al., 2001) (no. of CKD population = 13.0 million) and the anemic population that needs treatment with EPO will be 11.8 million. Ranging from 3 x 10^5 to 5 x 10^5 CKD patients in KSA is considered as the therapeutic burden of patients as they are in need of EPO therapy as per the estimated CKD population of KSA (estimated CKD patients: 1–2 million Saudis who comes from 5–10% of the 21 millions of total population) (Alsuwaida et al., 2010). It may be concluded that Jazan region of KSA shows the large prevalence of anemia among the CKD population and so the therapeutic burden is significantly high.

Conclusion:
Largely the prevalence of anemia as per definition by World Health Organization criteria was observed to be 69.0%, and both the severity and prevalence of anemia were found to be higher in the female gender. This cross-sectional study revealed the association of anemia with different stages of CKD as the severity and prevalence of anemia enhanced with the progression of the CKD. In summary, Jazan region of KSA shows the enormous prevalence of anemia among the CKD population and so reflecting the significantly high therapeutic burden which emphasizes the necessity of further analysis involving a bigger population and its feasible solution.

Ethical approval:
in accordance with the ethical standards of King Fahad central hospital research ethics committee (Registry no. 083) which the study was conducted (IRB approval number 083) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Acknowledgments:
The author would like to thank Albaha University for providing the assistance for this study.

Conflict of Interest:
The author has declared that no conflict of interest exists.

Funding:
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

REFERENCES
Akizawa T., Makino H., Matsuo S., Watanabe T., Imai E., Nitta K., Ohashi Y., Hishida A. And


نسبة شيوع فقر الدم في مرضى الكلى المزمن عالية جداً، ويرتبط شعورهم بتطور مرض الكلى المزمن طردياً.

رائد الحربى
قسم طب المختبرات، كلية العلوم الطبية التطبيقية، جامعة الباحة، الباحة، المملكة العربية السعودية.

يعتبر فقر الدم من الأعراض الشائعة المصاحبة لأمراض الكلى المزمنة، والتي تزداد شدتها مع تدهور أمراض الكلى المزمنة، مما يؤدي للإصابة بالكلى المزمنة، مما يؤدي للإصابة بالكلى المزمنة، مما يؤدي للإصابة بالكلى المزمنة، مما يؤدي للإصابة بالكلى المزمنة، مما يؤدي للإصابة بالكلى المزمنة.

تهدف هذه الدراسة لمعرفة نسبة حدوث فقر الدم لمرضى الكلى، بناءً على نتائج تحليل الدم.

الطريقة الدراسة
تم استخدام معادلة CKD-EPI لحساب معدل اتشريح eGFR، وتم تصنيف المرضى بأن لديهم فقر الدم بناءً على تركيز الهيموغLOBين بالدم، يعتبر مستوى الهيموغLOBين في الدم للمراة < 31 جم/ديسيلتر وكذلك < 31 جم/ديسيلتر للنساء مؤشر لفقر الدم. كما تم تصنيف المرضى لمجموعات بناءً على مستوى الهيموغLOBين في الدم إلى أربع مجموعات كالتالي: < 10 جم/ديسيلتر، 10-11 جم/ديسيلتر، 11-12 جم/ديسيلتر.

النتائج
الوزنن الدموغرافي لعينات البحث كانت ذكور/نساء = 123/106 (ذكور/نساء% = 59/41) مع معدل الأعمار 46.28 ± 17.98 و 54.94 ± 14.27 على التوالي. من إجمالي عدد المشاركين في هذه الدراسة (229) 157 مريض (69%) يعانون من فقر الدم، بينما 72 مريض، كانت نسبة الهيموغLOBين طبيعية. فقر الدم أكثر انتشاراً في النساء في هذه الدراسة من الرجال 36% مقابل 32%.

الخاتمة
نسبة شيوع فقر الدم في مرضى الكلى المزمن عالية جداً، ويرتبط شعورهم بتطور مرض الكلى المزمن طردياً.

ARABIC SUMMARY
شيوع فقر الدم في مرضى الكلى المزمن وشدته

Rania Al-Hashimi
Department of Laboratory Medicine, College of Applied Medical Sciences, Al-Baha University, Al-Baha, Saudi Arabia.

Anemia prevalence and severity in CKD

Consider anemia of the common symptoms accompanying chronic kidney disease, which increases in severity with worsening of chronic kidney disease, leading to the urgent need for blood transfusion and long-term hospitalization. This study aimed to determine the frequency of anemia in patients with kidney disease, based on blood test results.

Study Method
Using the CKD-EPI formula to calculate eGFR, and classify patients based on blood hemoglobin levels, with male levels of < 31 g/dL and female levels < 29.1 g/dL considered anemia. Patients were classified into four groups based on blood hemoglobin levels: < 10 g/dL, 10-11 g/dL, 11-12 g/dL, and > 12 g/dL.

Results
The demographics of the study samples were males/females = 123/106 (males/females% = 59/41) with average age 46.28 ± 17.98 and 54.94 ± 14.27 on average. From a total of 229 patients in this study, 157 patients (69%) suffered from anemia, while 72 patients, were normal hemoglobin levels. Anemia was more prevalent in women in this study than men 36% compared to 32%.

Conclusion
Anemia prevalence and severity in chronic kidney disease are high, and are associated with the progression of chronic kidney disease.